Cabaletta Bio, Inc.: Form 10-Q for the period ended Mar 31, 2022
Filed with the SEC on May 12, 2022 and accepted by EDGAR at May 12, 2022, 07:45 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2022-01-01 to 2022-03-31 | $9.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-01-01 to 2022-03-31 | −$13.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-01-01 to 2022-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-01-01 to 2022-03-31 | −$12.9m | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months2022-01-01 to 2022-03-31 | −$12.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2022-01-01 to 2022-03-31 | $147.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-03-31 | $59.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-03-31 | $111.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-03-31 | $113.7m | us-gaap:Assets |
| Current liabilities | At period end2022-03-31 | $6.9m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2022-03-31 | $106.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-22-019677. Last ingested by Listed: Nov 12, 2026, 17:57 ET. Listed shows no prices and gives no investment advice.